ARQT - יחס חוב להיוון בספרים Arcutis

Arcutis Biotherapeutics (ARQT) is integrating ESG principles into the development of dermatological products, focusing on bioethics and the reduction of production emissions. The business leverages demand from dermatologists and psoriasis patients, distributing innovative ointments through pharmacies and insurers. This price chart illustrates the asset's dynamics, where the indicator stands at 0.55. Patent protection of its unique non-hormonal formula allows the company to maintain premium pricing power.

This indicator determines the degree of the business's dependence on borrowed capital relative to its own book capital, allowing for an assessment of financial stability and bankruptcy risk. Analyzing the current "debt / book capitalization" ratio is critically important for Arcutis Biotherapeutics (ARQT), as high promotion costs for dermatological drugs and insurance coverage risks could increase the burden on capital.